Consensus statement on the management of dyslipidaemias in adults☆

Working group commissioned by the French Society of Endocrinology (SFE), the Francophone Society of Diabetes (SFD), The New French Society of Atherosclerosis (NSFA), S. Béliard a, F. Bonnet b, B. Bouhanick c, E. Bruckert d, B. Cariou e, S. Charrière f, V. Durlach g, P. Moulin f, ∗, R. Valéro a, B. Vergès g, h

a Service de nutrition, maladies métaboliques, endocrinologie, hôpital de la Conception, CHU de Marseille, AP–HM, 13009 Marseille, France
b Service d’endocrinologie-diabétologie, Inserm U1018, université Rennes 1, CHU de Rennes, Rennes, France
c Pole CVM, service d’HTA et thérapeutique, CHU Rangueil, université de Toulouse 3, 353059 Toulouse, France
d Service d’endocrinologie, hôpital Pitié Salpêtrière, Paris, France
e Inserm UMR 1087, clinique d’endocrinologie, Institut du thorax, université de Nantes, CHU de Nantes, 44000 Nantes, France
f Fédération d’endocrinologie, GHE, HCL, université de Lyon 1, Inserm UMR 1066 CARMEN, 69003 Lyon, France
g Pôle thoracique cardiovasculaire et neurologique, hôpital Robert-Debré, 31092 Reims, France
h Service d’endocrinologie, diabétologie et maladies métaboliques, CHU de Dijon, INSERM LNC UMR 866, Université Bourgogne Franche-Conté, 21000 Dijon, France

Keywords: Dyslipidemia; cardiovascular risk; Statins; Fibrates; Consensus statement; LDLc goal

1. Introduction

Most cases of dyslipidaemia increase the risk of ischaemic cardiovascular (CV) complications, while their treatment can reduce CV morbidity and mortality. There is, therefore, a broad international consensus for promoting treatment, although with some variations in approach. As previous French recommendations for dyslipidaemia treatment date back 10 years, they are no longer up to date and have been retracted. However, the complex and evolving differences between the recommendations of European societies (EAS/ESC) [1–3], the International Atherosclerosis Society (IAS) [4], and national bodies in the US (AHA/ACC) [5,6] and Great Britain (NICE) [7] mean that it has become necessary for practitioners to have an updated consensus statement informed by the latest clinical trials.

Thus, a synthesis integrating features from both American and European recommendations was created. A condensed version for the sake of simplicity is presented here, although readers may refer to the primary source documents via the references selected by members of the working group (WG). This consensus statement concerns the general population and does not address either familial hypercholesterolaemia [8–10] or diabetic dyslipidaemia [11,12] in detail. This text is consistent with the opinions of the WG, and has been validated by external readers from three of the societies involved and based on data from the literature available up to 2016.1

2. Initial evaluation

2.1. Identification of secondary dyslipidaemia

Secondary dyslipidaemia must be ruled out through investigation of the diseases and treatments that could cause hyperlipidaemia. This involves checking, when appropriate, thyroid-stimulating hormone (TSH), blood glucose, urine protein by dipstick and creatinineemia. Hypothyroidism and cholestasis can induce hypercholesterolaemia; however, the clinical context of cholestasis is generally suggestive. Nephrotic syndromes can cause severe mixed hyperlipidaemia. Diabetes, renal insufficiency and excessive alcohol consumption result

☆ A French version of this consensus was published in the Revue du praticien (September issue).
∗ Corresponding author. Fédération d’endocrinologie, hôpital cardiovasculaire Louis-Pradel, GHE, boulevard Pinel, 69003 Lyon, France.
E-mail address: Philippe.moulin@chu-lyon.fr (P. Moulin).

http://dx.doi.org/10.1016/j.jando.2016.11.001
0003-4266/© 2016 Published by Elsevier Masson SAS.

in hypertriglyceridaemia. The main treatments that increase low-density lipoprotein cholesterol (LDLc) and, often, triglycerides (TG) are cyclosporin, retinoids, corticosteroids, oral ethinylestradiol, certain antiretrovirals, certain neuroleptics and certain targeted therapies in oncology.

2.2. Estimation of CV risk

CV risk needs to be taken into consideration for adjusting the intensity of primary prevention measures (before the occurrence of atherothrombotic complications). Indeed, the risk/benefit ratio of the treatment and its efficacy (number of persons to be treated to avoid ischaemic complications) depend on the magnitude of the expected benefit. This is based on the level of absolute risk of the individual concerned. Risk-calculation models refer to the multifactorial risk of the general population and not to monogenic primary dyslipidaemias, such as familial hypercholesterolaemia, for which the level of risk is underestimated with general models. Risk-calculation models specific to diabetes patients are also available [13–15].

In practice terms, the WG recommends risk evaluation of the general population based on SCORE tables, which estimate the risk of ischaemic CV death at 10 years [adjusted for low-risk European countries, including France, and taking into account high-density lipoprotein cholesterol (HDLc)] [16]. When such tables are not available, the WG suggests pragmatic tallying of the standard cardiovascular risk factors (CVRF) as a substitution method (low CV risk: 0–1 CVRF; intermediate risk: 2 CVRF; high CV risk: ≥ 3 CVRF).

2.2.1. Risk factors and markers

The main CVRF to be taken into consideration in patients with dyslipidaemia are age and gender, family history of CV disease (first-degree relatives), tobacco use, arterial hypertension, decreases in HDLc, the presence of diabetes and severe to moderate chronic renal failure (CRF), (Table 1). These all contribute to risk estimation and treatment decision-making.

### Table 1

<table>
<thead>
<tr>
<th>Major cardiovascular risk factors (CVRF) to be considered in subjects with dyslipidaemia.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (men ≥ 50 years, women ≥ 60 years)</td>
</tr>
<tr>
<td>Ischaemic CV family history (men ≤ 55 years, women ≤ 60 years)</td>
</tr>
<tr>
<td>Current smoker or quit for &lt; 3 years</td>
</tr>
<tr>
<td>Hypertension</td>
</tr>
<tr>
<td>HDLc ≤ 0.40 g/L (≤ 1.0 mmol/L)</td>
</tr>
<tr>
<td>Type 2 diabetes (or type 1 diabetes for &gt; 15 years and age &gt; 40 years)</td>
</tr>
<tr>
<td>Renal failure (GFR &lt; 45 mL/min, &lt; 60 mL/min in young adults)</td>
</tr>
<tr>
<td>LDLc: high-density lipoprotein cholesterol; GFR: glomerular filtration rate.</td>
</tr>
</tbody>
</table>

2.2.1.1. Lipid tests. Lipid tests are needed at the baseline assessment for estimating the individual level of risk, and then during follow-up to evaluate the efficacy of treatment to ensure adherence, to motivate patients with respect to dietary and lifestyle measures, and to guide potential treatment intensification (A1) (Table 1). It is possible to conduct non-fasting lipid tests when the practitioner finds it necessary to facilitate screening in an elderly person or after an acute coronary syndrome (ACS) [17]. Reliability of the LDLc estimate is all the more affected when there is postprandial hypertriglyceridaemia. Although the role of HDLc as a contributory factor of CV protection has been called into question, its plasma determination provides a powerful marker of CV risk and must therefore be maintained in CV risk assessment (A1) [18].

Although no large-scale, double-blind clinical trials have been done with titration of a lipid-lowering treatment to attain an LDLc target, reference markers are necessary for determining the at-risk subject’s condition at inclusion and with treatment in relation to levels observed in CV prevention trials (C3). Cholesterol measurements unrelated to HDL [total cholesterol (TC) – HDLc] may be used in the event of hypertriglyceridaemia (HTG). This takes remnants into account and does not require LDLc assay; its value is 0.3 g/L (0.77 mmol/L) above the usual reference values used for LDLc (B2) [19]. Assay of apolipoprotein B (ApoB) plasma concentration does not provide major advantages for estimates of CV risk (B2). Its main clinical relevance is limited to the aetiological diagnosis of mixed hyperlipidaemia to differentiate familial combined hyperlipidaemia from dysbetalipoproteinaemia, in which ApoB is not increased.

Measurement of lipoprotein (a) [Lp(a)], a risk co-factor for familial hypercholesterolaemia and unexplained atherothrombotic states, should not be done systematically, as its assay indications are restricted (Table 2) [20].

### Table 2

<table>
<thead>
<tr>
<th>Indications for lipoprotein(a) [Lp(a)] assay.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Intermediate or high ischaemic cardiovascular (CV) risk with Early personal CV history</td>
</tr>
<tr>
<td>Recurrent ischaemic CV complications despite effective treatment with statins</td>
</tr>
<tr>
<td>Familial hypercholesterolaemia (heterozygous familial hypercholesterolaemia)</td>
</tr>
<tr>
<td>Family history of increased Lp(a)</td>
</tr>
</tbody>
</table>

Adapted from Catapano et al. [1], Stone et al. [5] and Nordestgaard [20].

2.2.1.2. Limitations and benefits of other risk markers. The benefits of employing other risk marker assays for clarifying the risk of subjects with dyslipidaemia remain a matter of debate.

2.2.1.2.1. Biological markers. Plasma concentration assays of fibrinogen, ultrasensitive C-reactive protein (us-CRP) [21], homocysteine (excluding unexplained atherothrombotic complications), lipoprotein-associated phospholipase A2 (Lp-PLA2) [22], lipoparticles (such as LpA1), and the identification of small dense LDL and microalbuminuria (apart from diabetes or hypertension) provide no adequate additional predictive value in dyslipidaemic patients.

2.2.1.2.2. Genotyping. In primary (genetic) hyperlipidaemia, genotyping patients at specialized expert centres enables characterization of the relevant disease (investigation of

---

2 Quotes (A1, B3) correspond to the level of evidence based medicine regarding the recommendation and quality of the literature.
2.2.1.4. Imaging

2.2.1.4.1. Carotid ultrasound. Measurement of carotid intima media thickness (IMTc), which is invaluable in clinical research as an integrated marker of risk, has insufficient predictive value in clinical practice for adjusting the prediction of CV events. Moreover, variability of its measurement due to the method of acquisition and software used hampers comparisons of two separate measurements [21,29]. The ability to reclassify ischaemic risk is limited, and its use in clinical practice is not recommended (B2). Detection of significant carotid plaques, however, may be a predictive integration tool and an opportunity to screen for severe carotid stenosis [30,31]. Nevertheless, severe stenosis is rare and usually arises in the context of high CV risk and/or confirmed polyvascular atheromatous disease. The WG recommends carotid ultrasound with plaque assessment when there is no access to a multislice computed tomography (CT) scan equipped to measure coronary calcium scoring in intermediate-risk patients (B2).

2.2.1.4.2. Coronary calcium scoring. Quantification of coronary calcifications using a CT scan without contrast injection is a method that uses little irradiation. A very high load of calcified atheromatous plaques suggests the presence of multiple non-calcified plaques (stenotic or non-stenotic); such a finding translates into a level of risk that may be equivalent to that observed in secondary prevention (A1). The results must be interpreted both as an absolute value (very high individual risk when the score exceeds 300–400 AU) and a relative value compared with the score of a similar population to assess the additional relative risk (calcium score >75% for age and gender) [32]. A zero score has a strong negative predictive value for CV ischaemia events. The level of reclassification is high in subjects with intermediate risk [23]. Its use could be effective for optimizing CV preventative measures in conditions of intermediate risk [33]. The WG recommends its use in this particular situation (B2).

2.2.1.4.3. CT coronary angiography. CT coronary angiography is not indicated in asymptomatic dyslipidaemic patients for assessing subclinical coronary atheroma except for unusual circumstances (C2). However, it may be used in subjects suspected to have stable coronary disease and who are at intermediate risk (B1). A functional test for investigating myocardial ischaemia is generally preferred (A1) [34].

3. Dietary approaches

Dietary measures are to be systematically implemented overall for both secondary and primary prevention since LDLc is >1.3 g/L (3.4 mmol/L, median for French adults) or when serum TG levels are >1.5 g/L (1.7 mmol/L, 90th percentile) (A1).

Individualized lifestyle modifications combining physical activity and supervised dietary intakes aimed at nutritional balance and not systematic weight loss [35] could have an impact on long-term CV risk [36,37]. Recommendations consist of implementing a Mediterranean-type diet, including olive oil and nuts (walnuts, hazelnuts, almonds, 30 g/day), which currently has the highest level of proof (A1) [38].

3.1. General nutritional recommendations for CV prevention

3.1.1. Lipid intakes

Total recommended lipid intake is around 25–35% of total caloric intake in adults (A2):

- saturated fatty acids (SFA) increase LDLc, and daily intakes should not exceed 8–10% of energy requirements [39,40]; they should be replaced with oleic acid and polyunsaturated fatty acids (A1) [41];
- trans-unsaturated fatty acids promote an increase of LDLc and decrease of HDLc. Their intake should be as low as possible from processed sources (<1%) [42];
- mono-unsaturated fatty acids decrease LDLc as a substitute for SFA. Several studies related to the Mediterranean diet suggest beneficial effects with olive oil consumption for
preventing CV events, and an intake of about 15% of total energy intake (TEI) is recommended (A1) [43];

- polyunsaturated fatty acids lower LDLc and, to a lesser extent, HDLc when they replace SFAs. When used excessively in the form of vegetable oil [omega-6 fatty acids (FA)], they upset the omega-3/omega-6 FA balance. An increased ratio is recommended at the expense of SFAs, but they should not exceed 10% of TEI (A2) [44].

Note: There is a very limited level of proof for supplementing with alpha-linolenic acid (ALA) and/or long-chain omega-3 FA (EPA, DHA) above the reference nutrient intake (RNI), according to several recent randomized trials [45]. The WG does not recommend the use of dietary supplements provided that nutritional needs (RNI) are met by a diversified diet, including fish (B1).

- reducing high-cholesterol foods has a variable effect on LDLc that is less than that obtained by adjusting the composition of FA. Moderation to < 300 mg/day is a common-sense measure recommended particularly with mixed intakes rich in SFAs, cholesterol and sodium chloride (such as cold cuts) (B2) [39].

3.1.2. Fibre intake

A daily intake of 30–45 g of fibre, including 5–15 g/day of soluble fibre, is recommended. Preference should be given to daily consumption of fruit (two portions) and vegetables (three portions) (A2) [46,47]. High intakes of fruit/fruit juices may increase hypertriglyceridaemia.

3.1.3. Alcohol consumption

As long as alcohol consumption is low to moderate [0.5–2 U/day (1 U = 10 g pure alcohol)], it is not discouraged as a CV preventative strategy due to its established association with a moderate reduction of CV risk [48]. This relationship, however, does not demonstrate causation and is independent of the type of alcohol ingested; meta-analyses of observational studies do not show a significant decrease in CV mortality [49].

3.2. Dietary supplements

3.2.1. Phytosterols

Supplementing with phytosterols remains controversial due to the lack of interventional studies for CV events [50]. At an effective dose (2 g/day), they lower LDLc by 10% [51]. There is no consensus within the WG on their systematic use in patients with hypercholesterolaemia or a high CV risk (C3) [52,53].

3.2.2. Red yeast rice (RYR)

RYR is in fact lovastatin, a first-generation statin, at low doses. The cholesterol lowering effect is not as strong as with statins with marketing authorization (MA), and the production process has not been perfected. Its safety profile is poorly documented. At present, the WG refers to warnings by the ANSM (National Agency for the Safety of Medicines and Health Products) and ANSES (French Agency for Food, Environmental and Occupational Health and Safety), and does not recommend the use of RYR products in the absence of sufficient quality-control procedures [54,55].

3.2.3. Policosanol

This has no conclusive cholesterol lowering effect, according to the latest, strictly controlled studies. Its use is therefore not recommended [56].

3.3. Influence of lifestyle on TG levels

It is recommended that there be a focus on weight reduction through physical activity and a balanced low-calorie diet in cases of overweight or obesity. The effects of discontinuing alcohol consumption are yet to be evaluated [57].

The proportion of carbohydrates in relation to TEI is limited to < 50%. Intakes of mono- or disaccharide simple sugars, particularly fructose, is reduced to < 10% of TEI. In cases of hypertriglyceridaemia, the consumption of sugary drinks is not recommended (sodas, fruit juice), and fruit should be taken in moderation (one per meal). When additional TG-lowering effects are desired through supplementing with omega-3 long-chain FA, only high intakes that are considerably greater than the RNI (≥ 2 g/day) have shown any such effects (B2).

Major hypertriglyceridaemia includes the risk of acute pancreatitis, which is considered moderate with TG levels > 10 g/L (11.3 mmol/L) and high with levels > 30 g/L (34 mmol/L). The implementation of strict fasting until TG levels return to the safe range is therefore a nutritional emergency (A3). It is advisable to seek a specialized opinion for possible additional exploratory tests and to choose a subsequently relevant dietary approach: for example, a diet drastically low in fat vs. a balanced low-calorie diet low in simple carbohydrates.

4. Primary prevention of hypercholesterolaemia and mixed dyslipidaemia

Risk-calculation tables are inadequate in heterozygous familial hypercholesterolaemia in both children and adults, as they do not incorporate duration of exposure to hypercholesterolaemia and, thus, underestimate the risk, particularly in young adults. There are specific recommendations for the diagnosis and therapeutic indications [8–10]. Screening for dyslipidaemia in first-degree relatives is recommended when LDLc is > 1.9 g/L (4.9 mmol/L) in an index case that establishes the diagnosis of familial hypercholesterolaemia. Clinical and biological predictive scores may support the aetiological diagnosis. It is essential to refer cases of severe heterozygous familial hypercholesterolaemia and children to specialized centres.

4.1. General treatment recommendations

Dietary measures are recommended for all patients except those with LDLc < 1.3 g/L and low CV risk (SCORE < 1%) (A1). In addition to dietary measures and promotion of regular physical activity, smoking cessation support is an important component of the CV prevention process (A1) [2].

For primary prevention in the general population, treatment decisions depend on 10-year CV risk assessment (SCORE calculation or tables, cumulative CVRF) (A2).
4.2. LDLc objectives and CV risk in primary prevention

The LDLc concentrations presented in Fig. 1 are thresholds for intervention or intensification, as well as the minimum target to be achieved.

4.2.1. Low CV risk [according to SCORE calculation: risk of CV death at 10 years < 1% or 0–1 CVRF (excluding diabetes)]

Statin treatment is overall rarely justified with low CV risk due to lack of effectiveness. The intervention threshold is 1.9 g/L (4.9 mmol/L), and treatment with a low-intensity statin (Table 4) is generally sufficient (A1).

4.2.2. Intermediate CV risk (risk of CV death at 10 years between ≥ 1 and < 5% or 2 CVRF)

The threshold is 1.30 g/L (3.4 mmol/L) (B2). This also includes diabetics with no additional risk factors. Statin treatment is usually advisable in this situation.

The HOPE-3 clinical trial explored primary prevention with intermediate risk (CV mortality in the placebo group projected over 10 years: 5.1%) and showed the effects of rosuvastatin 10 mg/day on major ischaemic CV events. Mean LDLc at inclusion was 1.27 g/L, with a mean LDLc decrease of 0.35 g/L vs. placebo [59,60].

---

Table 3
Situations with increased risks of muscle-related side-effects (non-exclusive list of indications).

- Renal or hepatic failure
- History of previous muscle intolerance to lipid-lowering agent
- History of myopathy
- Preexisting increase of creatine phosphokinase > 3 times normal
- Treatment with drugs that interfere with statin metabolism
  (immunosuppressors, antiretrovirals)
- Hypothyroidism
- Age > 75 years
- Asian origin
- Chronic alcohol use

Adapted from Catapano et al. [1], Stone et al. [5] and Hegele et al. [57].

Table 4
Treatment with statins according to their intensity.

<table>
<thead>
<tr>
<th>Statin Treatment</th>
<th>Low-intensity statin treatment</th>
<th>Moderate-intensity statin treatment</th>
<th>High-intensity statin treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td>LDLc decrease</td>
<td>LDLc decrease &lt; 30%</td>
<td>LDLc decrease &lt; 50%</td>
<td>LDLc decrease &gt; 50%</td>
</tr>
<tr>
<td>Fluvastatin</td>
<td>Atorvastatin</td>
<td>Atorvastatin</td>
<td>Rosuvastatin</td>
</tr>
<tr>
<td>20–40 mg</td>
<td>10–20 mg</td>
<td>40–80 mg</td>
<td></td>
</tr>
<tr>
<td>Pravastatin</td>
<td>Fluvastatin 80 mg</td>
<td>Pravastatin 40 mg</td>
<td>Rosuvastatin 20 mg</td>
</tr>
<tr>
<td>10 mg</td>
<td>Simvastatin 40 mg</td>
<td>Simvastatin 20–40 mg</td>
<td>Rosuvastatin 5–10 mg</td>
</tr>
<tr>
<td>Simvastatin 5 mg</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Adapted from Stone et al. [5].

LDLc: low-density lipoprotein cholesterol.
This target, however, may be adjusted, and the final decision must take into account the:

- patient’s preferences;
- presence of disease associated with increased CV risk, such as chronic inflammatory disease (rheumatoid arthritis), radiation therapy including the heart area, moderate CRF [glomerular filtration rate (GFR) < 60 mL/min] in young subjects;
- presence of subclinical atheroma more serious than expected for age (verified by advanced carotid plaques or a high calcium score), as this reclassifies the subject into the high CV risk category.

4.2.3. High CV risk (risk of CV death at 10 years ≥ 5% or ≥ 3 CVRF)

The purpose of primary prevention treatment in these patients is to maintain LDLc at < 1 g/L (A1). This is the most commonly recommended target for type 2 diabetes, as these patients generally have at least one coexisting CVRF.

Special categories of patients at very high CV risk may warrant more ambitious targets (LDLc < 0.7 g/L). This small, select group includes patients presenting with diabetes and target-organ involvement (confirmed nephropathy, stage 2+ retinopathy: moderate preproliferative) or with > 2 CVRF in addition to diabetes (A2). In cases of haemodialysis or renal transplantation, there are no longer any indications for introducing a statin at this stage (B2); however, statins that were started previously during the severe CRF stage need not be discontinued (C2).

4.3. Special cases of mixed dyslipidaemia

The most recent epidemiological data suggest that hypertriglyceridaemia has independent proatherogenic effects even in the absence of diabetes or the metabolic syndrome (MetS) [61–63]. However, the atherogenicity of hypertriglyceridaemia is less intense overall than that of hypercholesterolaemia, and LDLc remains the priority target in terms of CV prevention (Fig. 2). As a result, the presence of mixed hyperlipidaemia with moderate hypertriglyceridaemia (< 5 g/L) does not change the therapeutic management for isolated hypercholesterolaemia [64,65]. The dietary and lifestyle guidelines concerning hypertriglyceridaemia are given together with those of hypercholesterolaemia, as they play particularly important roles in controlling hypertriglyceridaemia (A1). The process of using cholesterol lowering agents is the same for high or very high risk in primary prevention (B3).

![Flowchart](https://example.com/flowchart.png)

**Fig. 2.** Treatment options in the presence of hypertriglyceridaemia. LDLc calculation cannot be used in cases of hypertriglyceridaemia > 4 g/L. If necessary, direct measurement, ApoB assay or calculation of non-HDL cholesterol can be applied. Only fenofibrate + statin was used in large-scale clinical trials; the combination of gemfibrozil + statin is contraindicated. CV: cardiovascular; TG: plasma triglycerides; LDLc/HDLc: low-density/high-density lipoprotein cholesterol; ω-3 FA: omega-3 fatty acids.
4.3.1. Mixed dyslipidaemia including moderate hypertriglyceridaemia [<5 g/L (5.6 mmol/L)]

4.3.1.1. LDLc is on target using dietary/lifestyle measures and/or statins. With moderate hypertriglyceridaemia (2–5 g/L), fibrates are an option only if two other conditions are also met (B3) [66–69]: low HDLc (<0.4 g/L); and high or very high CV risk.

Specialist advice is recommended for a statin/fibrate combination (B2) [70]. Due to its risk of drug interactions, gemfibrozil is contraindicated in combination with statins and, therefore, fenofibrate should be used (B3).

4.3.1.2. LDLc is not on target despite dietary/lifestyle measures and/or statins. The priority is to reach the LDLc target by using and titrating a statin (A1). If the statin is at the optimal dose and dietary/lifestyle measures have been used, yet LDLc is still not on target, then ezetimibe should be added to the statin (B2) [71].

4.3.2. Mixed dyslipidaemia including high hypertriglyceridaemia (>5 g/L)

Use of a first-line fibrate is mainly for hypertriglyceridaemia >5 g/L, and resistant to dietary/lifestyle measures, with the aim of reducing the risk of acute pancreatitis via a decrease in TG levels (B3). However, there are no controlled clinical trials to validate this hypothesis [72]. Specialist advice is necessary in cases of treatment-resistant hypertriglyceridaemia or severe hypercholesterolaemia.

5. Management of hypercholesterolaemia and mixed dyslipidaemia for secondary prevention of ischaemic CV complications

Only one randomized, open-label, study has been done using dosage titration for achieving an LDLc target <0.8 g/L [73]. During this trial of patients with stable coronary insufficiency, mean LDLc decreased to 0.95 g/L in the intervention group vs. 1.10 g/L. Benefit was seen for the composite primary endpoint and non-fatal infarction.

Baseline plasma concentrations of LDLc and those obtained with treatment during clinical trials also provide objective reference points for directing treatments. In meta-regression interventional studies, a linear relationship is retained between the magnitude of LDLc decrease and reduction of relative risk (RR) of major ischaemic events, and the gain in RR persists in subgroup analyses of LDLc levels close to 0.7 g/L, but with a simultaneous increase in the number of people to be treated [74].

It is recommended that a high-intensity statin be used from the outset for secondary prevention (atorvastatin 80 mg), except in cases of LDLc that is not high at baseline and/or with a significant risk of muscle side effects (Table 3). The increased risk of type 2 diabetes is largely offset by the reduced risk of recurrent ischaemic complications.

An LDLc target <0.70 g/L (1.8 mmol/L) is recommended (A2). This threshold is based on:

- results of randomized controlled trials (RCTs) testing treatment strategies using high-intensity vs. lower-intensity statin treatments [75–79];
- results of IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial) [80];
- consideration of extrapolations from meta-analyses and analyses of extreme subgroups [74,81–83].

If the LDLc target is not reached by monotherapy using the maximum tolerated statin dose, the addition of ezetimibe should be considered (A2). During IMPROVE-IT, intensification of the cholesterol lowering treatment decreased LDLc from 0.7 g/L to 0.54 g/L, with a significant 2% reduction in absolute value of the primary endpoint. This enabled one major ischaemic event to be avoided through the annual treatment of 300 people [80]. Other studies are now being conducted to explore lower LDLc targets, with some proposing a target of 0.5 g/L (1.3 mmol/L). The effectiveness (cost/efficacy ratio) of such objectives needs to be evaluated.

When the maximum treatment dose fails to decrease LDLc to <0.7 g/L, a 50% reduction of LDLc is considered an acceptable compromise [1,5]. Nevertheless, a patient who maintains a high LDLc despite such a reduction continues to have a high residual CV risk.

In the event of adverse reactions with a high-dose statin or statin–ezetimibe combination, the use of a low- to moderate-dose statin with an LDLc target <1 g/L is recommended (C1). In the event of statin intolerance, monotherapy with ezetimibe or even cholestyramine should be used (C2).

In cases of associated hypertriglyceridaemia, the strategy considered for mixed dyslipidaemia (see Section 4.3.1 above) should be used.

If LDLc remains >2 g/L in secondary prevention with the maximum tolerated treatment, the patient should be referred to a specialized centre for consideration of LDL apheresis (A3).

6. Other special situations

6.1. Management of isolated hypertriglyceridaemia

People with a history of major hypertriglyceridaemia (>10 g/L) require a specialist’s opinion (Fig. 2). Dietary and physical activity measures play a central role in controlling isolated hypertriglyceridaemia (A1). Secondary factors, such as diabetes and MetS, are particularly common with hypertriglyceridaemia and need to be addressed.

6.1.1. Persistent hypertriglyceridaemia ≥5 g/L despite dietary/lifestyle measures

A fibrate should be used as the first-line monotherapy (A1). In cases of persistent hypertriglyceridaemia ≥5 g/L despite dietary/lifestyle measures and fibrate therapy at optimal doses, high-dose omega-3 long-chain FA (>2 g/day of EPA/DHA) may be added after specialist consultation (C3). While these products are no longer reimbursed in France as medications, they are available as dietary supplements. If hypertriglyceridaemia persists at ≥5 g/L despite dietary/lifestyle measures and fibrate
therapy at optimal doses, and LDLc levels are not on target despite the patient’s RR (measured by a direct method or by non-HDLc determination), a statin could be added to fenofibrate following specialist consultation (C3).

6.3.2. Moderate isolated hypertriglyceridaemia (2–5 g/L) despite dietary/lifestyle measures
CV risk estimates take precedence:
- if the risk is low to intermediate, there is no need to add a fibrate;
- if it is high with LDLc on target, the use of a fibrate should be considered, as per the Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial (VA-HIT) and Helsinki Heart Study (HHS) [84,85].

6.2. HDLc < 0.30 g/L with no secondary factors

It is important to seek a specialist’s opinion for establishing the aetiological diagnosis and evaluating the opportunity for treatment. The decision is based on investigation of subclinical atheroma. If there is reclassification to a high CV risk, a statin should be proposed, although the level of proof is limited due to the lack of specific clinical trials of this setting (B3).

6.3. Elderly people (> 75 years)

When epidemiological studies are carried out with adjustment of health status indicators (albumin, iron, etc.), a positive relationship between LDLc and CV risk is found even in elderly populations [86–89]. Meta-analyses and the PROSPER study have shown CV benefit from statins in the elderly [90–92], and several cohort studies have found no increased risk of cancer or cognitive impairment.

Identification of hypercholesterolaemia in elderly subjects with no CV history should prompt investigations for possible secondary dyslipidaemia (C3).

In the elderly, initiation or continuation of treatment with a statin needs to be considered on the basis of comorbidities and the potential benefit that the treatment may provide (C2).

It is advisable to continue statin treatment after the age of 75 years in subjects who are already being treated and tolerate the treatment (B1) [1].

For primary prevention, if associated CV risk factors and advanced non-complicated atheroma are present, the use of low-dose statin treatment in those aged 75–80 years should be carefully weighed. The decision should take into account the absence of severe comorbidities; secondary hyperlipidaemia should also be ruled out and a low dose selected (B2) [1,5].

For secondary prevention, it is advisable to treat elderly subjects with a statin for an LDLc target value < 1.0 g/L (B2).

7. Conclusion

This consensus statement is based on information that has heterogeneous levels of proof and is supported by analyses of the continually evolving literature. Genetic dyslipidaemia has specific recommendations, as estimates of risk and treatment implications differ. There are specific consensuses for these situations. The present synthesized recommendation addresses the general population of subjects with dyslipidaemia and CV risk. Given the prevalence of diabetes and renal failure and their attendant CV risks, and the secondary dyslipidaemia observed in these situations, some reference markers have been provided for these populations, including specific recommendations for their management. Following the emergence of generic statins, and the subsequent period of cost reductions, for the treatment of dyslipidaemia, the development of new, more expensive, drugs will soon require reevaluation of certain indications with the aim of providing optimal management and treatment based on efficacy as well as cost.

Document review group

F. Boccaro, Paris, NSFA; M. Farnier, Dijon, NSFA; B. Feve, Paris, SFE; P. Gourdy, Toulouse, SFE; B. Guerci, Nancy, SFD; M. Krempf, Nantes, SFD.

Disclosure of interest

The participants declare having scientific activities involving earnings or research funding (conferences, clinical trials or research grants) during the years 2012–2016.

Working group

S Béliard: Aegerion Pharmaceuticals, Amgen, Isis (now Ionis) Pharmaceuticals, MSD, Novartis, Novo Nordisk, Sanofi.
F. Bonnet: Amgen, AstraZeneca/Bristol-Myers Squibb, Boehringer Ingelheim, Coca-Cola, ISA, Eli Lilly, MSD, Novo Nordisk, Sanofi, Takeda Pharmaceutical.
B. Bouhanick: AstraZeneca, Eli Lilly, Novo Nordisk, Sanofi.
E. Bruckert: Aegerion Pharmaceuticals, Amgen, Chiesi, Danone, Genfit, Ionis Pharmaceuticals, MSD, Eli Lilly, Regeneron, Rottapharm MEDA, Sanofi, Unilever.
S. Charriere: AstraZeneca, Boehringer Ingelheim, Eli Lilly, Merck Serono, MSD, Novartis, Novo Nordisk, Sanofi.
V. Durlach: AstraZeneca, Amgen, Bioprojet Pharma, Sanofi.
B. Vergès: AstraZeneca/Bristol-Myers Squibb, Bayer Pharma, Janssen Pharmaceutical, MSD, Novartis Pharma, Novo Nordisk, Novartis, Sanofi, Servier, Takeda Pharmaceutical.
Document review group

F. Boccara: Amgen, Bristol-Myers Squibb, Janssen Pharmaceutical, MSD, Regeneron, Sanofi, Gilead, ViViHealthcare.
M. Farnier: Mylan/Abbott Laboratories, Akcea Therapeutics/Ionis Pharmaceuticals, Amgen, AstraZeneca, Eli Lilly, Kowa American Corporation, Merck & Co, Pfizer, Roche Diagnostics, Sanofi/Regeneron, Servier.
B. Feve: AstraZeneca/Bristol-Myers Squibb, Sanofi Aventis, GlaxoSmithKline, Novartis, Novo Nordisk, Janssen Pharmaceutical, MSD, Eli Lilly, Boehringer Ingelheim, Intarcia Therapeutics, MetaCure, Pfizer, MSD, Roche Diagnostics, Medtronic, A. Menarini Diagnostics, Abbott Laboratories, VitaLaire, Dinno Santé, Orkyn, ViViHealthcare.
B. Guerci: Abbott Laboratories, AstraZeneca/Bristol-Myers Squibb, Boehringer Ingelheim, Dinno Santé, Eli Lilly, Intarcia Therapeutics, Janssen Pharmaceutical, GSK, Medtronic, A. Menarini Diagnostics, MetaCure, MSD, Novartis, Novo Nordisk, Orkyn, Pfizer, Roche Diagnostics, Sanofi Aventis, VitaLaire.
M. Krempf: AstraZeneca, Amgen, Boehringer Ingelheim, Danone, Eli Lilly, Ionis Pharmaceuticals, Janssen Pharmaceutical, A. Menarini Diagnostics, MSD, Novartis, Novo Nordisk, Sanofi, Unilever.

Acknowledgements

The logistics related to setting up these guidelines were supported by an unrestricted grant from the French Society of Endocrinology.

References

52  


[48] De Jong A, Plut J, Bast A, Godschalk RW, Basu S, Mensink RP. Effects of plant stanol and sterol ester consumption on lipid metabolism, antiox-


[51] http://www.anses.fr/fr/content/compl%C3%A9ments-alimentaires-%C3%A9valu%C3%A9s-par-l%20-Anses/compl%C3%A9ments-alimentaires-associ%C3%A9s-à-l%20-asséchage%20-%20Points-d%27information%20-%20CAZ-et%20-m%C3%A9canismes-mises-en-garde-de-l-%20-ANSM-Point-d%27information%20-%28language%29/ fre-FR.

[52] Berthold HK, Unverdorben S, Degenhardt R, Buitla M, Gouni-Berthold I. Effect of policosanol on lipid levels among patients with hyperchole-
sterolemia or combined hyperlipidemia: a randomized controlled trial. JAMA 2006;295:2262–9.


